source
- Leo Pharma signs $435 million deal with Tanabe for rare skin disease drug dersimelagonLeo Pharma announced a licensing agreement with Mitsubishi Tanabe Pharma for worldwide rights to dersimelagon, an oral melanocortin-1 receptor agonist targeting rare genetic skin disorders. The dr…
- Eli Lilly signs up to $370M ion-channel collaboration with OmniAbEli Lilly has entered a collaboration with antibody platform company OmniAb that could involve up to $370 million in research, development and commercial milestone payments. OmniAb, which was spun…